ONLUNIFY Trademark

Trademark Overview


On Wednesday, January 26, 2022, a trademark application was filed for ONLUNIFY with the United States Patent and Trademark Office. The USPTO has given the ONLUNIFY trademark a serial number of 97240202. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, May 31, 2024. This trademark is owned by Eli Lilly and Company. The ONLUNIFY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases. Applican...
onlunify

General Information


Serial Number97240202
Word MarkONLUNIFY
Filing DateWednesday, January 26, 2022
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, May 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 13, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases. Applicant expressly excludes eye drops and ophthalmic solutions and eye treatments

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, May 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Saturday, January 29, 2022NEW APPLICATION ENTERED
Monday, January 31, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 4, 2022ASSIGNED TO EXAMINER
Tuesday, November 8, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, January 12, 2023EXTENSION OF TIME TO OPPOSE RECEIVED
Monday, January 30, 2023ASSIGNED TO PETITION STAFF
Wednesday, January 18, 2023TEAS POST PUBLICATION AMENDMENT RECEIVED
Monday, February 6, 2023CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Tuesday, February 28, 2023EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, April 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, June 1, 2023SOU TEAS EXTENSION RECEIVED
Thursday, June 1, 2023SOU EXTENSION 1 FILED
Thursday, June 1, 2023SOU EXTENSION 1 GRANTED
Saturday, June 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 30, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Friday, May 31, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Friday, May 31, 2024ABANDONMENT - AFTER PUBLICATION
Monday, December 4, 2023SOU EXTENSION 2 GRANTED
Monday, December 4, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 4, 2023SOU EXTENSION 2 FILED